What is the ticker symbol for Heat Biologics?

Heat Biologics trades under the ticker HTBX on AMEX.

What sector does Heat Biologics operate in?

Heat Biologics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze HTBX in a portfolio?

PortView shows HTBX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Heat Biologics (HTBX) Stock Analysis

AMEXHealthcareBiotechnology

$2.38+0.42%

1-year price historyRange $2.10 – $6.53

52-week range$2.38

$1.60$10.85

What Heat Biologics does

Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

Key metrics

Market cap

$61.07M

P/E (TTM)

-2.07

EPS (TTM)

$-1.15

Beta

0.30

Dividend yield

0.00%

Revenue / share

$0.04

50-day avg

$2.57

200-day avg

$4.11

52-week high

$10.85

52-week low

$1.60

CEO

Jeffrey Wolf

ETFs linked to HTBX

Broad-market and Healthcare sector ETFs an investor holding Heat Biologics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how HTBX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze HTBX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Heat Biologics?: Heat Biologics trades under the ticker HTBX on AMEX.
Which exchange is HTBX listed on?: HTBX is listed on AMEX.
What sector does Heat Biologics operate in?: Heat Biologics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze HTBX in a portfolio?: PortView shows HTBX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.